Michael Gelband’s Cymabay Therapeutics CBAY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-177,072
| Closed | -$4.18M | – | 2079 |
|
|
2023
Q4 | $4.18M | Buy |
177,072
+163,441
| +1,199% | +$2.91M | 0.03% | 381 |
|
|
2023
Q3 | $203K | Buy |
+13,631
| New | +$181K | ﹤0.01% | 1521 |
|
|
2022
Q3 | – | Sell |
-13,535
| Closed | -$40K | – | 2409 |
|
|
2022
Q2 | $40K | Sell |
13,535
-26,690
| -66% | -$63.8K | ﹤0.01% | 1811 |
|
|
2022
Q1 | $125K | Buy |
40,225
+4,730
| +13% | +$14.9K | ﹤0.01% | 1977 |
|
|
2021
Q4 | $120K | Buy |
+35,495
| New | +$135K | ﹤0.01% | 1926 |
|
|
2021
Q3 | – | Sell |
-28,719
| Closed | -$125K | – | 2789 |
|
|
2021
Q2 | $125K | Buy |
28,719
+10,980
| +62% | +$48.7K | ﹤0.01% | 2104 |
|
|
2021
Q1 | $81K | Buy |
+17,739
| New | +$95.5K | ﹤0.01% | 2003 |
|
|
2020
Q4 | – | Sell |
-19,971
| Closed | -$145K | – | 2485 |
|
|
2020
Q3 | $145K | Sell |
19,971
-72,021
| -78% | -$385K | ﹤0.01% | 1553 |
|
|
2020
Q2 | $321K | Buy |
+91,992
| New | +$265K | 0.01% | 1288 |
|
|
2019
Q3 | – | Sell |
-18,142
| Closed | -$130K | – | 1710 |
|
|
2019
Q2 | $130K | Sell |
18,142
-35,861
| -66% | -$406K | 0.01% | 998 |
|
|
2019
Q1 | $717K | Buy |
+54,003
| New | +$574K | 0.05% | 247 |
|
Other funds holding CBAY
Michael Gelband's CBAY Position: Q1 2024 in Review
Michael Gelband sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 177,072 shares — an estimated $4.18M sold.
Michael Gelband first reported a position in CBAY in Q1 2019 and held it in 11 quarters. The position peaked at $4.18M in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.
- Michael Gelband reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
- Michael Gelband sold 177,072 Cymabay Therapeutics shares in Q1 2024, an estimated $4.18M.
- Michael Gelband first reported a position in Cymabay Therapeutics in Q1 2019 and held it in 11 quarters.
- Michael Gelband's Cymabay Therapeutics position peaked at $4.18M in Q4 2023.
- 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.
Based on ExodusPoint Capital Management's 13F filing for Q1 2024, filed 14 May 2024.